Onconova Therapeutics, Inc. (ONTX): Price and Financial Metrics
ONTX Price/Volume Stats
| Current price | $1.00 | 52-week high | $1.45 |
| Prev. close | $1.00 | 52-week low | $0.55 |
| Day low | $0.77 | Volume | 1,281,800 |
| Day high | $1.00 | Avg. volume | 96,681 |
| 50-day MA | $0.79 | Dividend yield | N/A |
| 200-day MA | $0.81 | Market Cap | 20.90M |
ONTX Stock Price Chart Interactive Chart >
Onconova Therapeutics, Inc. (ONTX) Company Bio
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer.
Latest ONTX News From Around the Web
Below are the latest news stories about ONCONOVA THERAPEUTICS INC that investors may wish to consider to help them evaluate ONTX as an investment opportunity.
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell LymphomaPreclinical data show that narazaciclib treatment led to significant tumor growth inhibition, demonstrating synergy with standard-of-care ibrutinib, in ibrutinib-sensitive and -resistant settings Early Phase 1/2 studies suggest potential for an improved profile and daily dosing Dose escalation is underway in lead indication of Low Grade Endometrioid Endometrial Carcinoma (LGEEC), with plans to define the Recommended Phase 2 Dose (RP2D) and prepare for registrational studies, with a planned updat |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning! |
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’sDifferentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compared to approved CDK4/6 inhibitors Data support the potential use of narazaciclib in breast and ovarian cancers Narazaciclib progressing towards RP2D and preparation for registrational studies, with a planned update in H1 2024 NEWTOWN, Pa., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc |
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity ConferenceNEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President & CEO, will present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference, being held December 3-5, 2023 at Florida Atlantic University, Executive Education Complex, |
Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Call TranscriptOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome to Onconova Therapeutics Third Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, November 14, 2023. At this time, I would like […] |
ONTX Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | 15.22% |
| 1-year | 27.39% |
| 3-year | -79.59% |
| 5-year | -95.83% |
| YTD | 34.12% |
| 2023 | 15.47% |
| 2022 | -74.68% |
| 2021 | -63.50% |
| 2020 | 21.62% |
| 2019 | -81.85% |
Continue Researching ONTX
Want to see what other sources are saying about Onconova Therapeutics Inc's financials and stock price? Try the links below:Onconova Therapeutics Inc (ONTX) Stock Price | Nasdaq
Onconova Therapeutics Inc (ONTX) Stock Quote, History and News - Yahoo Finance
Onconova Therapeutics Inc (ONTX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...